{
  "docId": "019de06f-55b4-734a-a2e3-c1019ed629b5",
  "docSlug": "42b17c6fff3e2006bf9fc5d84bd6edcc",
  "documentTitle": "Pershing Square | Activist Presentation Deck | 120 slides",
  "authorId": "pershing-square",
  "authorName": "Pershing Square Capital Management, L.P.",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2014-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2955465,
  "pageNumber": 59,
  "pageCount": 120,
  "prevPage": 58,
  "nextPage": 60,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a news excerpt to illustrate a specific legal vulnerability.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de06f-55b4-734a-a2e3-c1019ed629b5/59",
  "deckHref": "/decks/019de06f-55b4-734a-a2e3-c1019ed629b5",
  "deckJsonHref": "/decks/019de06f-55b4-734a-a2e3-c1019ed629b5.json",
  "deckAnchorHref": "/decks/019de06f-55b4-734a-a2e3-c1019ed629b5#slide-59",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.92,
        "x": 0.04,
        "y": 0.44
      },
      "kind": "callout",
      "text": "Allergan loses Latisse patent fight, jeopardizing up to $200M in sales\n“The U.S. Court of Appeals for the Federal Circuit in Washington has deemed a pair of Latisse patents invalid, paving the way for Novartis' Sandoz unit and the generics maker Apotex to sell their copies. The patents on Latisse--a variation of Allergan's Lumigan, used to treat glaucoma--cover ways to apply the drug to promote eyelash growth. But that growth is a ‘known potential side effect’ of glaucoma treatments, the court ruled, rendering Allergan's patent claims obvious.”\n- Fierce Pharma; June 11, 2014",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1eacddc-0a8d-4f80-9407-b18bca520299",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.04,
        "y": 0.19
      },
      "kind": "list",
      "text": "Risk of successful patent challenges greatest for “Life Extension” patents\nAllergan recently received negative news on Latisse, which employs the same active ingredient used in another AGN product, Lumigan",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a69a462-eb54-404d-969d-8326bc785fda",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.75,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Generics Manufacturers May Challenge Existing Patents",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "773cfa35-b8d6-4593-b900-9779f4264ec3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "476d7d58-a0f2-4f9d-b86f-d12e61df50ef",
      "evidence": "Citing Fierce Pharma news report to validate the risk claim.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 70,
      "from": 55,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f8b5116e-058e-4e92-b495-aa8e556924d9",
      "evidence": "The document highlights the risks of Allergan's business model and the benefits of the deal",
      "position": 1,
      "objective": "To highlight the risks of not taking action",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}